Print

ImmunoGen, Inc. (IMGN) Announces Clinical Data Presentations at the 54th American Society of Hematology Annual Meeting and Exposition  
12/3/2012 11:06:21 AM

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that there will be clinical data presentations on two compounds that utilize the Company’s TAP technology at the 54th annual meeting of the American Society of Hematology (ASH) to be held December 8-11, 2012 in Atlanta, GA.
//-->